EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the recommended treatment strategy in patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations, especially with common mutations including exon 19 deletion and exon 21 L858R mutation (1–4).